Sorafenib With TACE to Treat Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the feasibility to combine sorafenib with
transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The
hypothesis is that sorafenib may prevent the development and growth of tumoral lesions not
treated by chemoembolisation.